ИСТИНА

Nowadays the prevalence of hepatobiliary system diseases is extremely increasing. According to the data of the World Health Organization, there are more than 2 billion people in the world, who are suffering from liver diseases, which is about 1/3 of the world's population. One of the most common groups of liver diseases is hepatosis. The standard therapy includes hepatoprotective drugs, obesity reduction drugs and insulin resistance restoration drugs, but today there are no effective drugs against hepatosis. Thus, modern pharmacology requires the active study and discovery of new hepatoprotective drugs, including those of plant origin. Polyprenols have great potential as hepatoprotective agents. They are transformed into dolichols by hydrogenation in the liver. Dolichols are directly involved in the synthesis of cell membrane glycoproteins, being donors of oligosaccharides in the process of N-glycosylation of proteins through asparagine (the dolichol-phosphate cycle). It is one of the mechanisms of hepatoprotective action: the process of regeneration and renewal of liver cells is accelerated. Another mechanism of hepatoprotective action of polyprenols is suppressing oxidative stress through non-selective neutralization of free radicals. Polyprenols from Ginkgo biloba are the closest forms to endogenic dolichols by the number of isoprene units and their isomerism. This is one of the reasons, why they are of high scientific interest. Our research group plans to optimize and validate the technique of polyprenols extraction by non-polar organic solvents from Ginkgo biloba leaves, to develop a method of obtaining the high purity polyprenols substance from Ginkgo biloba leaves and to study physicochemical properties of this substance, to investigate the chemical composition of impurities by HPLC, TLC and spectral analysis methods; to design techniques of the qualitative and quantitative determination of polyprenols in the substance; to explore the hepatoprotective properties of a substance of Ginkgo biloba’s polyprenols in experimental modeling of fatty liver dystrophy; to study the stability of obtained substance during storage by accelerated aging method. The results of experimental studies can serve as the basis for the creation of regulatory documentation and the subsequent state registration of the pharmaceutical substance of high-purity polyprenols obtained from Ginkgo biloba leaves. In the future this substance will be used for the development of medicines.